Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Lentigo maligna denotes flat, pigmented lesions predominantly in areas of actinic damage that have the propensity to become malignant. More than 10 years may pass before lentigo maligna evolves into an invasive neoplasma. As an invasive process, it is termed lentigo maligna melanoma (LMM), and it has the potential for both lymphatic and hematogenic metastases. Because of the size and location of the lesions, cosmetically unsatisfactory scars may result from conventional surgery. Therefore, alternative means of treatment, including cryosurgery, have been employed. We report on 12 patients suffering from lentigo maligna who had been treated successfully by cryosurgery between 1984 and 1990. The average follow-up period was 51.4 months, and the recurrence rate was 8.3 percent. Knowing that microinvasive components can be demonstrated in 15 percent of lentigo maligna lesions, we retrospectively reassessed our patients by immunohistochemical procedures with S-100 protein. Although intradermal microinvasion could be confirmed in one patient, no recurrence had been observed within 61 months of follow-up. Provided that patients are selected properly and extension of cryonecrosis is monitored, cryosurgery may prove an efficient alternative to conventional surgery in the treatment of lentigo maligna.
 ...
PMID:Cryosurgery of lentigo maligna. 151 89

Melanocytic cells from white Angora goats were studied in vivo and in vitro. The histopathology of pigmented areas of skin from the most common sites of melanoma (solar-exposed areas of the ear, face, and perineum) resembled that of the epidermal melanocytes in Hutchinson's melanotic freckle in humans. Seven melanoma biopsies from 6 Angora goats showed histopathological features in common with human melanoma. A melanoma cell line, GM-1, was established in culture from a lymph node metastasis obtained from an animal that had a primary tumor excised and later developed extensive metastatic disease. GM-1 cells were mainly diploid, amelanotic, proliferated rapidly, spontaneously formed vacuolated cells, and were tumorigenic in nude mice. The species of origin of the GM-1 line was confirmed by isozyme profiles. GM-1 cultured cells and the original biopsy both expressed S-100 protein and tyrosinase antigen. Using GM-1 cells as the immunogen, a monoclonal antibody (MoAb 1F1) was derived that reacted strongly with a 116 kDa antigen in 50% of the GM-1 cells, but had little activity with goat fibroblasts (GM-F) or with human melanoma cells. GM-F, on the other hand, yielded more intense staining than GM-1 with an intermediate filament antibody (IFA), reacting with a 58 kDa antigen in both cell lines. The sensitivity of GM-1 to anticancer agents was similar to that of human melanoma cells. The pathology of caprine melanoma and its association with sun-exposed sites in relatively young animals suggest that it may be a suitable model for studying induction of melanoma by natural sunlight.
 ...
PMID:Histopathology of melanocytic lesions in goats and establishment of a melanoma cell line: a potential model for human melanoma. 210 29

A clinical and histologic review of 25 patients with melanocytic lesions classified as desmoplastic malignant melanoma is reported. All of the lesions were located in sun-exposed sites. The average age was 61.2 years (range, 38 to 83), with a median age of 56. There were 14 female and 11 male patients. Desmoplastic malignant melanoma is a melanocytic and fibroblastic proliferation that occurs predominantly in the head and neck area. The bland constituent cells resemble fibroblasts and are often arranged in bundles or fascicles, which may be arrayed perpendicularly to the overlying epidermis. Enlarged and/or atypical cells are usually scattered among the spindled cells. Most, but not all, of the tumors (24 of 25 in this series) are associated with lentigo maligna or an atypical junctional melanocytic proliferation. Mitotic figures are always found within the constituent cells of the fibrous-appearing mass, and neurotropism may be present. Patients with desmoplastic melanoma typically present with a mass, which is occasionally associated with a pigmented lesion. The lesions in our series were deeply invasive to level IV or V. Lentigo maligna and a dermal fibroblastic-appearing mass containing atypical cells arranged in fascicles are the most common morphologic features found in desmoplastic melanoma. Follow-up data is available for 23 patients. The average length of follow-up was 2.7 years (range, 0.1 to 9 years). Eighteen patients were observed for 3 or more years. Twelve patients developed local recurrences, and five developed metastases; three of the patients with metastases had a local recurrence before the development of metastases. Three of the patients with metastatic melanoma died of tumor between 2 and 4 years after their initial excision. Eight of the 12 locally recurring lesions were either diagnosed initially as a benign lesion or histologic examination was not performed on the initial excision specimen. It appears that recurrence may be related to inadequate initial therapy.
 ...
PMID:Desmoplastic malignant melanoma. A clinicohistopathologic study of 25 cases. 316 15

Lentigo maligna, a precancerous lesion, is a brown-black irregularly pigmented freckle, usually occurring on the face of the elderly subject. In a series of 99 patients with malignant melanomas, lentigo maligna was the pre-existing lesion in 21. The clinical and histological findings, and previous publications on the subject are reviewed. Lentigo maligna itself is not a superficial malignant melanoma. After the development of malignant melanoma from lentigo maligna, eight of 21 patients developed metastatic disease. This seems to indicate that once malignant melanoma has developed (whether de novo from the junctional portion of a pre-existing nevus, or from a lentigo maligna), the outlook is the same. During the development of malignant melanoma from lentigo maligna there is an indefinite period when it is virtually impossible to determine histologically whether malignant melanoma is present. Naturally, the inclusion of these indefinite cases will greatly influence reported results of treatment.
 ...
PMID:Lentigo maligna and malignant melanoma. 592 2

Lentigo maligna (LM) and lentigo maligna melanoma (LMM) are distinct entities from other forms of melanoma, occurring predominantly on the skin of the head and neck in elderly people, having a slow growth rate and a low metastatic potential (10%). Twenty-three patients with LM were treated with conventional fractionated irradiation, 18 were locally controlled and two failed locally both of whom, however, were salvaged with further treatment. Three patients are not evaluable because of short follow-up time. Median time to complete regression of the lesion is seven months. Twenty-eight patients with LMM have been irradiated, 23 are locally controlled, two locally recurred (both retrieved with subsequent treatment), and three are inevaluable because of short follow-up time. One patient with a level 5 LMM has developed regional and distant metastases. It is concluded that irradiation is a simple effective method of treatment for this form of melanoma.
 ...
PMID:Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. 686 69

The main object of this review was to examine the various histogenetic types of melanoma in order to determine their nature. Nodular melanoma and superficial spreading melanoma differ in the more rapid growth of the former. For tumors of equal depth of invasion in patients of the same sex, the prognoses are similar. Clinical features with prognostic significance are sex, age, and site of the lesion. Women have a decided superiority in survival up to the age of about 50 years when their superiority declines. Survival rates for men also decline after the age of 50 years but to a lesser degree. Melanomas of the extremities have a better prognosis than melanomas of the axial regions. The histological feature of most prognostic significance is depth of invasion (thickness). Ulceration is partly bound to thickness of the lesion, but has an augmentative effect of its own which is related to rate of growth. Thin lesions with or without regression are often associated with metastases. Melanomas arising in Hutchinson's melanotic freckle have a better prognosis than nodular or superficial spreading melanoma but there has not been any series large enough for definitive markers with prognostic significance to be determined. A similar state pertains in palmar, plantar and subungual melanomas. The initial surgical approach in nodular and superficial melanoma should be based upon the thickness of the tumour, site of the tumour, and sex of the patient. The current classification of malignant melanoma is unsatisfactory. Melanoma arising in Hutchinson's melanotic freckle seems to be a distinct entity. Melanomas of other histogenetic types would be best classified according to site.
 ...
PMID:The nature of melanoma. A critical review. 704 99

Malignant melanoma is the most serious skin tumor and its incidence is doubling every ten years. Ultraviolet rays represent the main environmental cause of melanoma. Among the constitutional factors identified, two clinicopathological forms of naevus are considered to be important epidemiological precursors: acquired dysplastic naevi and congenital giant naevi. Four clinical and histological types are distinguished: SSM (Superficial Spreading Melanoma), NM (Nodular Melanoma), LMM (Lentigo Maligna Melanoma), arising from Dubreuilh melanosis, ALM (Acral Lentiginous Melanoma). Thickness constitutes the essential prognostic factor. Clinical examination is the only recommended standard assessment. Chest x-ray is useful, and acts as a reference for subsequent follow-up. Other complementary investigations are requested as a function of clinical signs. Treatment is exclusively surgical. The lateral resection margins are 0.5 cm for melanoma in situ, 1 cm for melanomas less than 1 mm thick, 2 cm for melanomas between 1 and 4 mm thick, and 3 cm for melanomas thicker than 4 mm. Chemotherapy is mainly used in the treatment of metastatic melanoma. There is no indication for radiotherapy apart from palliative treatment of nonsurgical metastases. New therapies such as immunotherapy and gene therapy are under investigation.
 ...
PMID:[Malignant melanoma]. 992 73

Lentigo maligna (LM) is well known as an irregularly pigmented macular lesion usually presenting on the sun-damaged head and neck of older patients. Lentigo maligna (LM) has the potential to develop into invasive melanoma (LMM). A method of surgical excision for the treatment of LM and LMM using paraffin sections with tissue mapping to ensure clear margins before delayed defect closure is described. The results of applying this method in the treatment of 66 cases over a 40 month period are presented. Thirty-eight per cent of cases required two excisions or more to clear the tumour and 32% of cases showed evidence of invasive melanoma. Only one case has recurred thus far, and none have developed metastatic disease.
 ...
PMID:Surgical treatment of lentigo maligna and lentigo maligna melanoma. 1009 85

Although melanoma was historically thought to be radiation resistant, there are limited data to support the use of adjuvant radiation therapy for certain situations at increased risk for locoregional recurrence. High-risk primary tumor features include thickness, ulceration, certain anatomic locations, satellitosis, desmoplastic/neurotropic features, and head and neck mucosal and anorectal melanoma. Lentigo maligna can be effectively treated with either adjuvant or definitive radiation therapy. Some retrospective and prospective randomized studies support the use of adjuvant radiation to improve regional control after lymph node dissection for high-risk nodal metastatic disease. Consensus on the optimal radiation doses and fractionation is lacking.
...
PMID:The role of radiation therapy in melanoma. 2524 66